Yu Mi Ahn

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Bryan D. Smith, Michael D. Kaufman, Wei-Ping Lu et al. · Cancer Cell · 2019 · 277 citations

Medicine, Oncology, Pharmacology +17

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

Wayne W. Chan, Scott Wise, Michael D. Kaufman et al. · Cancer Cell · 2011 · 207 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14

A Convenient Method for the Efficient Removal of Ruthenium Byproducts Generated during Olefin Metathesis Reactions

Yu Mi Ahn, KyoungLang Yang, Gunda I. Georg · Organic Letters · 2001 · 182 citations

Natural Sciences, Chemical Engineering, Chemistry +14

Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against <i>BRAF</i> or <i>RAS</i> Mutant Tumor Cells

James R. Henry, Michael D. Kaufman, Sheng-Bin Peng et al. · Journal of Medicinal Chemistry · 2015 · 85 citations · Full text

Medicine, Oncology, Pharmacology +17

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

Bryan D. Smith, Michael D. Kaufman, Cynthia B. Leary et al. · Molecular Cancer Therapeutics · 2015 · 77 citations

Medicine, Oncology, Pharmacology +17